Biotech Values

[DewDiligence]

>I don't think NM-283 is necessarily dead meat if the riba combo bombs, either. It will just make things much more difficult.<

What IDIX investors should be rooting for is an outcome where ribavirin is allowed to be given with NM283 in phase-3 but ends up adding little or nothing to the mix. I.e., the best outcome in phase-3 would be superiority of NM283+pegifn vs SoC and non-inferiority of NM283+pegifn vs NM283+riba+pegifn.